Ligand validation:2WHR

PE4: 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2WHR_PE4_B_1548	27%	74%	0.216	0.869	0.46	0.53	-	-	8	0	96%	0.9583
3ZLV_PE4_B_1545	52%	45%	0.165	0.93	0.54	1.59	-	1	5	0	96%	0.9583
3ZLT_PE4_A_1545	48%	42%	0.17	0.944	0.56	1.73	-	5	2	0	83%	0.8333
5OV9_PE4_B_607	31%	11%	0.234	0.911	0.61	3.72	-	9	2	0	96%	0.9583
4QIB_PE4_A_201	74%	58%	0.103	0.934	0.7	0.91	-	1	0	0	100%	1
4E0K_PE4_C_101	68%	45%	0.074	0.952	0.7	1.43	-	-	0	0	63%	18.12
4EWL_PE4_A_401	68%	56%	0.125	0.936	0.7	0.96	-	1	6	0	100%	0.9704
5UY9_PE4_A_300	66%	65%	0.123	0.927	0.5	0.82	-	1	3	0	100%	1
2ITK_PE4_A_300	65%	71%	0.112	0.913	0.46	0.64	-	1	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.